Azellon Cell Therapeutics
London
About Azellon Cell Therapeutics
Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.2M
- Last round: Series Unknown (Mar 2015)
- Website: azellonctx.com
- Phone: 0208 712 0253
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/azellon-cell-therapeutics-2428085 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.